Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.44 |
| ▸ | CDK2 | P24941 | 20/20 | 0.44 |
| ▸ | CCND1 | P24385 | 16/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 16/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | RB1 | P06400 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033697 | 0.86 | CCNE1 (0.42) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27065324 | 0.85 | EGFR (0.33) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27033339 | 0.84 | CCNE1 (0.42) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27033396 | 0.83 | CCND1 (0.41) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27061902 | 0.82 | CCNE1 (0.45) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL30804792 | 0.81 | CCNE1 (0.51) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27174705 | 0.81 | CCNE1 (0.51) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27060376 | 0.79 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL30726199 | 0.77 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL27033323 | 0.77 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDK3, CDK1 | CCNE1 53/4885CDK2 5/4885CCND1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.